Download presentation
Presentation is loading. Please wait.
Published byRosaline McDonald Modified over 9 years ago
1
Molecular Monitoring in CML the process and questions we can answer Letizia Foroni
2
Aims Review laboratory tests used for the diagnosis of CML Review the information provided by PCR Stopping treatment: how can molecular test help to decide
3
Process of analysis Sample collection and analysis Sample examination
4
The first step: look down a microscope! Increased number of one type of cells, the granulocytes o called because they contain a lot of granules!
5
Other diagnostic tools to confirm the diagnosis? Cytogenetic analysis
6
Chr 9 Chr 22: Ph chromosome Cytogenetics: Philadelphia chromosome
7
Philadelphia chromosome
8
Other diagnostic tools to confirm the diagnosis? Molecular analysis
9
Sample processing and RNA extraction
10
PCR analysis
11
Molecular Monitoring post TKI therapy Are the remaining blood cells normal or leukaemic? For this we require a very sensitive methodology: Real Time PCR or Quantitative PCR
12
BCR-ABL1: FU analysis Real time quantitative PCR
13
What information does the PCR test provide?
14
PCR results
16
Conversion Factor PCR and International Scale Values Lab 1 Lab 2 Lab 3 Procedure 1 Procedure 2 Procedure 3 Reference material 0.75 0.55
17
Effect of Conversion factor/s on tests from different laboratories
18
Monitoring CML summary
19
European Leukaemia Network Guidelines
20
When is it important to test? At diagnosis Every 3 months for at least the first 2 years (general practice) but to be discussed with your clinical team. Every 6 months after 2 years.
21
Monitoring CML summary CAN we stop?
22
The best method to use to decide when is best to stop Which and when?
23
Digital PCR
24
Conclusions PCR provides the most sensitive method to monitor disease Samples at 3 months and every three months predict future outcome Digital PCR is helping to identify patients who can consider stopping therapy
Similar presentations
© 2025 SlidePlayer.com. Inc.
All rights reserved.